Capitol Federal Financial (CFFN) investors sentiment increased to 1.76 in Q3 2018. It’s up 0.72, from 1.04 in 2018Q2. The ratio has increased, as 60 investment professionals opened new and increased holdings, while 34 decreased and sold positions in Capitol Federal Financial. The investment professionals in our database now hold: 105.18 million shares, up from 104.29 million shares in 2018Q2. Also, the number of investment professionals holding Capitol Federal Financial in top ten holdings was flat from 1 to 1 for the same number . Sold All: 8 Reduced: 26 Increased: 45 New Position: 15.
Analysts expect InflaRx N.V. (NASDAQ:IFRX) to report $-0.41 EPS on April, 4.After having $-0.31 EPS previously, InflaRx N.V.’s analysts see 32.26% EPS growth. The stock increased 2.40% or $0.89 during the last trading session, reaching $37.95. About 319,323 shares traded or 235.44% up from the average. InflaRx N.V. (NASDAQ:IFRX) has risen 63.49% since March 2, 2018 and is uptrending. It has outperformed by 63.49% the S&P500. Some Historical IFRX News: 17/05/2018 – InflaRx 1Q Loss EUR10.3M; 17/05/2018 – InflaRx 1Q Loss/Shr EUR0.04; 08/03/2018 – INFLARX ANNOUNCES FIRST PATIENT ENROLLED IN PHASE llB TRIAL WITH LEAD CANDIDATE IFX-1 IN HIDRADENITIS SUPPURATIVA; 29/03/2018 – InflaRx Full Year 2017 Financial & Operating Results; 29/03/2018 – lnflaRx Full Year 2017 Financial & Operating Results; 08/03/2018 – lnflaRx announces first patient enrolled in Phase llb trial with lead candidate IFX-1 in Hidradenitis Suppurativa; 08/05/2018 – INFLARX N.V. REPORTS CLOSING OF PRIMARY, SECONDARY OFFERING; 29/03/2018 – InflaRx FY Loss/Shr EUR2.6; 08/03/2018 InflaRx announces first patient enrolled in Phase IIb trial with lead candidate IFX-1 in Hidradenitis Suppurativa; 03/05/2018 – INFLARX PRIMARY, SECONDARY OFFERINGS PRICES AT $34.00 PER SHARE
The stock increased 0.52% or $0.07 during the last trading session, reaching $13.44. About 245,894 shares traded. Capitol Federal Financial, Inc. (CFFN) has risen 1.04% since March 2, 2018 and is uptrending. It has outperformed by 1.04% the S&P500. Some Historical CFFN News: 31/05/2018 – CAPITOL FEDERAL FINANCIAL INC -; 30/04/2018 – Capitol Federal Financial 2Q EPS 17c; 31/05/2018 – CAPITOL FEDERAL FINANCIAL-BOARD OF CAPITOL FEDERAL SAVINGS BANK ANNOUNCED THAT IT VOTED TO MAKE CAPITAL DISTRIBUTION TO CFFN IN AMOUNT OF $36.0 MLN; 18/04/2018 Capitol Federal® Financial, Inc. Announces Quarterly Dividend; 09/05/2018 – Mesirow Financial Investment MGT Exits Capitol Federal; 31/05/2018 – Capitol Federal Savings Bank to Make Capital Distribution of $36 Million to CFFN; 31/05/2018 – Capitol Federal Financial Board Declared True Blue Capitol Div of 25c/Share; 31/05/2018 – Capitol Federal® Financial, Inc. Announces True Blue® Capitol Dividend; 30/04/2018 – CAPITOL FEDERAL 2Q EPS 17C, EST. 19C; 30/04/2018 – Capitol Federal Financial: Deal Represents Value of $47.08/CCB Shr
Capitol Federal Financial, Inc. operates as the holding firm for Capitol Federal Savings Bank that provides various retail banking services and products in the United States. The company has market cap of $1.90 billion. The firm accepts a range of deposit products comprising savings accounts, money market accounts, interest-bearing and noninterest-bearing checking accounts, and certificates of deposits. It has a 20.06 P/E ratio. It also provides various loan products, such as one- to four-family residential real estate loans; construction-to-permanent loans; consumer loans comprising home equity loans and lines of credit, home improvement loans, auto loans, and loans secured by savings deposits; and commercial real estate loans consisting of various property types, including hotels, office and retail buildings, senior housing facilities, and multi-family dwellings located in Texas, Missouri, Kansas, Colorado, Arkansas, California, and Montana.
More notable recent Capitol Federal Financial, Inc. (NASDAQ:CFFN) news were published by: Seekingalpha.com which released: “Capitol Federal Financial declares $0.085 dividend – Seeking Alpha” on October 17, 2018, also Nasdaq.com with their article: “Capitol Federal Financial, Inc. (CFFN) Ex-Dividend Date Scheduled for November 15, 2018 – Nasdaq” published on November 14, 2018, Nasdaq.com published: “CFFN Makes Notable Cross Below Critical Moving Average – Nasdaq” on January 30, 2019. More interesting news about Capitol Federal Financial, Inc. (NASDAQ:CFFN) were released by: Streetinsider.com and their article: “Capitol Federal Financial (CFFN) Declares $0.39 Cash True-Up Dividend; 3.2% Yield – StreetInsider.com” published on October 26, 2018 as well as Seekingalpha.com‘s news article titled: “Capitol Federal to acquire Capital City Bancshares – Seeking Alpha” with publication date: April 30, 2018.
Knott David M holds 2.85% of its portfolio in Capitol Federal Financial, Inc. for 690,400 shares. Dean Investment Associates Llc owns 363,632 shares or 0.65% of their US portfolio. Moreover, Rocky Mountain Advisers Llc has 0.32% invested in the company for 7,250 shares. The Netherlands-based Robeco Institutional Asset Management B.V. has invested 0.28% in the stock. American Century Companies Inc, a Missouri-based fund reported 20.18 million shares.
InflaRx N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing inhibitors using C5a technology primarily in the United States and Europe. The company has market cap of $973.88 million. The Company’s C5a is an inflammatory mediator involved in the enhancement of a variety of autoimmune and other inflammatory diseases. It currently has negative earnings. The company’s lead product candidate is IFX-1, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that is in the Phase IIb clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; to treat ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and for the treatment of other chronic/autoimmune diseases.
Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.